FDA plans meeting on compounded peptides amid Kennedy pressure

FDA announces July meeting to review seven peptides for compounding pharmacy access, responding to Kennedy's pressure.

Objective Facts

The FDA announced Wednesday it will ask a panel of outside advisers to review seven peptides at a meeting in July, specifically whether they should be added to a list of substances that can be safely produced by pharmacies. The meeting announcement follows repeated pledges by Health Secretary Robert F. Kennedy Jr. to loosen regulations on peptides, which are often pitched as a quick way to build muscle, heal injuries or appear younger. In 2023, the FDA's panel of pharmacy advisers voted overwhelmingly that the peptides did not meet the criteria for safe compounding, with FDA regulators agreeing the substances "present significant safety risks," because most have not been extensively tested in humans. The FDA's pharmacy panel currently has vacancies which Kennedy could fill before the July meeting. Kennedy previewed the move in an interview with Joe Rogan, telling him "I'm a big fan of peptides" and that he'd "used them myself and with really good effect on a couple of injuries."

Left-Leaning Perspective

BioCentury published a critical analysis arguing that Kennedy announced the peptide deregulation "without using the formal regulatory process, presenting the move to a scientific advisory committee or, apparently, notifying FDA staff," and that his "casual announcement bypassed" the deliberative scientific review that had already occurred. ProPublica reported that despite few clinical studies supporting peptide safety or efficacy, Kennedy—who described himself as a "big fan" of peptides and has used them himself—is pushing the FDA to reverse its 2023 restrictions, which the agency had based on safety concerns. Critics warn that deregulation will not eliminate the gray market but create a second, seemingly medically legitimized channel, and that "if injectables can reach consumers without human trial data by executive fiat, the foundation of the drug approval system is eroded." ProPublica quoted a former FDA official questioning why peptides should receive different treatment than pharmaceuticals: "They're totally unapproved drugs... Would you let a pharmaceutical company do this? No way." Healthcare Dive raised concerns that "ideology and politics are fueling the FDA's actions rather than science," noting that under Kennedy "the FDA has been charting its own path, offering quick reviews to companies 'aligned with U.S. national priorities' and issuing a series of controversial decisions." Critics also note a supply chain and national security dimension, with many raw peptide ingredients appearing to come from Chinese manufacturers flowing through online vendors with no oversight or accountability. Chemical biologist Eileen Kennedy (of UNC Eshelman School of Pharmacy) told NPR that "without rigorous testing, it's unknown if the compounds could have unintended, harmful effects."

Right-Leaning Perspective

Republican Senator Tommy Tuberville of Alabama sent letters to Kennedy requesting peptide deregulation, and the compounding industry argues that FDA's restrictions have spawned an illicit market of imported chemicals from China and other countries not subject to U.S. drug standards. Kennedy echoed this argument on Rogan's podcast, saying "With the gray market you have no idea if you're getting a good product" and "a lot of this stuff that we've looked at is just very, very substandard." Hims & Hers, a telehealth company with commercial interest in peptide compounding, praised the FDA's action, with CEO Pat Carroll stating the FDA's plans "is an important step toward moving these treatments out of the gray market, and into more trusted channels overseen by vetted healthcare professionals." Scott Brunner, CEO of the Alliance for Pharmacy Compounding, told NPR that "the black market and the gray market are running amok" and that "American consumers would be a lot better off if the FDA would allow compounding of peptides that have a demonstrated track record of safety." Supporters cite Kennedy's argument that moving peptides to a category where "they can be studied, where we know what the source is, they're coming from legitimate formulators who are getting them from FDA-inspected labs" would improve access and safety compared to unregulated online vendors. Kennedy framed the action as a "long-overdue action to restore science, accountability and the rule of law" designed to shift demand away from illicit suppliers.

Deep Dive

In September 2023, the FDA's pharmacy advisory panel voted overwhelmingly that seven peptides did not meet criteria for safe compounding, with FDA regulators citing "significant safety risks" due to lack of extensive human testing. Now, Health Secretary Kennedy—who has publicly pledged to loosen peptide restrictions—has triggered a July 2026 FDA meeting to reconsider those same restrictions. Critically, the FDA's pharmacy panel has vacancies that Kennedy can fill before the July meeting, creating potential for panel composition changes. This structural fact underlies the core disagreement about process integrity. The compounding industry argues FDA restrictions created illicit markets for imported peptides from China and elsewhere, with Kennedy echoing concerns that gray-market products are "very, very substandard." Critics counter that deregulation will create a second, "more seemingly medically legitimized" channel rather than eliminating the gray market, and that it would expand access to unapproven drugs without the human safety evidence FDA normally requires. Kennedy claims the FDA acted illegally when it restricted the peptides in 2023, and he describes himself as a "big fan" who has used them personally for injuries. The key factual dispute involves process: critics argue Kennedy announced the deregulation on Joe Rogan's podcast "without using the formal regulatory process" and bypassed prior scientific review, while supporters argue he is properly invoking the July advisory committee process. A secondary debate centers on evidence sufficiency: supporters point to decades of clinical and research use, while opponents emphasize the absence of rigorous human trials required for new drugs. The July meeting outcome will be telling—historically, FDA advisory committees have almost always accepted expert advice, but under Kennedy the FDA "has been charting its own path, offering quick reviews to companies 'aligned with U.S. national priorities' and issuing a series of controversial decisions."

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

FDA plans meeting on compounded peptides amid Kennedy pressure

FDA announces July meeting to review seven peptides for compounding pharmacy access, responding to Kennedy's pressure.

Apr 15, 2026· Updated Apr 16, 2026
What's Going On

The FDA announced Wednesday it will ask a panel of outside advisers to review seven peptides at a meeting in July, specifically whether they should be added to a list of substances that can be safely produced by pharmacies. The meeting announcement follows repeated pledges by Health Secretary Robert F. Kennedy Jr. to loosen regulations on peptides, which are often pitched as a quick way to build muscle, heal injuries or appear younger. In 2023, the FDA's panel of pharmacy advisers voted overwhelmingly that the peptides did not meet the criteria for safe compounding, with FDA regulators agreeing the substances "present significant safety risks," because most have not been extensively tested in humans. The FDA's pharmacy panel currently has vacancies which Kennedy could fill before the July meeting. Kennedy previewed the move in an interview with Joe Rogan, telling him "I'm a big fan of peptides" and that he'd "used them myself and with really good effect on a couple of injuries."

Left says: Critics contend Kennedy bypassed formal regulatory process and scientific review when he announced the peptide deregulation on Joe Rogan's podcast. They argue deregulation will create a second gray market, normalize unproven drug access without human safety evidence, and weaken "a century of drug safety law."
Right says: Supporters argue FDA restrictions created dangerous black markets, and Kennedy told Rogan that with the gray market "you have no idea if you're getting a good product" and "a lot of this stuff that we've looked at is just very, very substandard."
✓ Common Ground
Both skeptics and supporters acknowledge that most peptides have not been extensively tested in humans and that the FDA previously cited them as presenting "significant safety risks."
Both compounding-industry proponents and critics acknowledge the existence of a gray market problem—though they disagree whether regulated compounding is the solution or would coexist with the gray market.
Some voices across perspectives recognize that involving licensed physicians and regulated compounding pharmacies would be preferable to uncontrolled online ordering, though they differ on whether the peptides themselves are safe enough for any route to market.
Objective Deep Dive

In September 2023, the FDA's pharmacy advisory panel voted overwhelmingly that seven peptides did not meet criteria for safe compounding, with FDA regulators citing "significant safety risks" due to lack of extensive human testing. Now, Health Secretary Kennedy—who has publicly pledged to loosen peptide restrictions—has triggered a July 2026 FDA meeting to reconsider those same restrictions. Critically, the FDA's pharmacy panel has vacancies that Kennedy can fill before the July meeting, creating potential for panel composition changes. This structural fact underlies the core disagreement about process integrity.

The compounding industry argues FDA restrictions created illicit markets for imported peptides from China and elsewhere, with Kennedy echoing concerns that gray-market products are "very, very substandard." Critics counter that deregulation will create a second, "more seemingly medically legitimized" channel rather than eliminating the gray market, and that it would expand access to unapproven drugs without the human safety evidence FDA normally requires. Kennedy claims the FDA acted illegally when it restricted the peptides in 2023, and he describes himself as a "big fan" who has used them personally for injuries.

The key factual dispute involves process: critics argue Kennedy announced the deregulation on Joe Rogan's podcast "without using the formal regulatory process" and bypassed prior scientific review, while supporters argue he is properly invoking the July advisory committee process. A secondary debate centers on evidence sufficiency: supporters point to decades of clinical and research use, while opponents emphasize the absence of rigorous human trials required for new drugs. The July meeting outcome will be telling—historically, FDA advisory committees have almost always accepted expert advice, but under Kennedy the FDA "has been charting its own path, offering quick reviews to companies 'aligned with U.S. national priorities' and issuing a series of controversial decisions."

◈ Tone Comparison

Left-leaning critics use urgent, protective language—BioCentury's headline warns the move "threatens the foundations of drug safety" and states it "should alarm everyone else." By contrast, Kennedy and supporters frame the action using restorative language—"long-overdue action to restore science, accountability and the rule of law"—positioning deregulation as correction of prior overreach.